Introduction
Actin filaments are the main cytoskeletal elements that regulate dendritic spine stability [1] . Actin cytoskeletal changes play a fundamental role in diseases of the central nervous system [2] [3] [4] , and actin-based mechanisms are critical in the neural circuit function needed for learning and memory [5] .
Acute stimulation of N-methyl-D-aspartate (NMDA) receptors induces dendritic spine loss and F-actin reorganization within 5-10 min [6] [7] [8] . Such NMDA-induced F-actin reorganization (NIFAR) is characterized by rapid depolymerization of F-actin in dendritic spines and accumulation of aberrant filaments within the dendritic shaft. Here, we used NIFAR as an in-vitro model of sublethal neuronal damage to test the hypothesis that the mood stabilizer lithium can prevent or reduce sublethal injury to excitatory neurons.
Lithium is a commonly used treatment for mood disorders, particularly bipolar disorder. However, despite being in clinical use for over 50 years, its mechanisms of action as a mood stabilizer still remain unclear [9] [10] [11] [12] [13] . Numerous studies have demonstrated that lithium has significant neuroprotective actions against a variety of insults [9] [10] [11] [12] [13] , including traumatic brain injury [14] .
This neuroprotective property of LiCl may underlie its therapeutic efficacy in mood disorders [9] [10] [11] [12] [13] . However, although volume reductions in specific brain areas have been described [12] , for most neuropsychiatric disorders there is little direct evidence that cell death is responsible for the cognitive and behavioral disturbances that characterize the disease. It seems more likely that any physical disruption of the neural circuitry associated with such disorders might occur on a more subtle level, involving dendritic and axonal branches and their synapses. Indeed, several neuropsychiatric disorders are characterized by loss or deformation of dendritic spinesthe dynamic, actin-rich membrane protrusions of excitatory synapses [1, 2, 4] .
Although lithium has multiple molecular targets, its ability to inhibit glycogen synthase kinase 3 (GSK3) activity has consistently been implicated in its neuroprotective properties [9] [10] [11] [12] [13] 15] . Our findings described here implicate inhibition of GSK3 as one of the potential mechanisms for protection against NMDA-induced early, sublethal changes to the actin cytoskeleton by lithium. Moreover, results on using specific antidepressants suggest that stabilization of the actin cytoskeleton may be a common mechanism shared by multiple classes of mood stabilizing compounds.
Methods

Ethics statement
The Institutional Animal Care and Use Committee of the University of California San Diego specifically approved this study under protocol #S07290. All surgical procedures were terminal, and deep anesthesia with isoflurane was used to prevent any pain or discomfort.
Cell culture
Hippocampal cultures containing a natural mixture of neurons and glia were prepared and maintained according to the method used by Calabrese et al. [16] . Cells were plated at a density of 300 cells/mm 2 and maintained in neurobasal medium (Gibco, Grand Island, New York, USA), supplemented with B27 (Invitrogen, Grand Island, New York, USA) or Neurocult SM1 neuronal supplement (STEMCELL Technologies, Vancouver, British Colombia, Canada) and 0.5 mM L-glutamine (Sigma, Aldrich, St. Louis, Missouri, USA).
Drugs
All drugs were purchased from Sigma-Aldrich, St. Louis, Missouri, USA. All experiments used coverslips from the same preparation as controls, which were treated with vehicle alone.
Immunocytochemical analysis
Cultures were fixed using 3.7% formaldehyde in PBS plus 120 mM sucrose for 20 min at 37°C. They were then incubated in 20 mM glycine for 5 min, rinsed and permeabilized with 0.2% Triton X-100 for 5 min at room temperature, and then blocked for 30 min with 2% BSA. Thereafter, the cultures were incubated for 1 h at room temperature with primary rabbit anti-MAP2 antibodies (1 : 2000) [17] . After rinsing with PBS, cells were incubated in the presence of 2% BSA with AlexaFluor488-conjugated secondary antibodies (Invitrogen, Grand Island, New York, USA) and with AlexaFluor568-phalloidin at a dilution of 1 : 1000 (Molecular Probes; Invitrogen, Grand Island, New York, USA) for 45 min at 37°C to label F-actin. Coverslips were washed twice with PBS and mounted using Aqua-Mount (Thermo Scientific, Pittsburgh PA, USA).
Quantitative image analysis
The fraction of neurons characterized by NIFAR was quantified directly under a microscope, by an investigator blind to the experimental condition, using a manual cell counter to count all MAP2-positive neurons and all NIFAR-positive cells while scanning the entire 12-mm round coverslip, excluding an area within ∼ 600 µm of the edge. Sample sizes are indicated in all figure legends.
Statistics
Statistical significance was set at the 95% confidence level (two-tailed) and calculated using Prism (Graphpad Software, La Jolla, CA, USA). Values are presented as mean SEM.
Statistical tests for each assay are defined in the corresponding figure legends. Pharmacological experiments were statistically compared with their corresponding vehicle control experiments.
Results
Lithium prevents NIFAR
In control neurons, phalloidin staining revealed the typical distribution pattern for F-actin within glutamatergic pyramidal neurons, the prevalent neuronal cell type in these cultures. F-actin exhibits a characteristic enrichment in dendritic spines, with greatly reduced concentrations within the soma and dendrites ( We found that a 7-day preincubation with 3 mM LiCl substantially reduced NIFAR ( Fig. 1a and c) ; a 1 day preincubation had a lesser but still statistically significant effect (Fig. 1c ). Shorter preincubations with LiCl (12 and 1 h) did not protect against NIFAR. Using a 7-day preincubation protocol, we observed a dose-dependent effect of LiCl in preventing NIFAR, with both 2 and 1 mM, but not 0.3 mM, LiCl showing significant protection (Fig. 1d ). Higher concentrations of LiCl (5-20 mM) induced extensive neuronal cell death, without detectable astrocyte cell death.
GSK3 inhibition prevents NIFAR
As many of the effects of lithium are known to be mediated through its direct and/or indirect inhibition of GSK3 [9] [10] [11] 15] , we tested whether inhibition of GSK3 has a similar neuroprotective effect on NIFAR. Consistent with this hypothesis, preincubation for 1 h or 7 days with the specific GSK3 inhibitor SB216763 (10 µM) significantly protected against NIFAR (Fig. 2a) . Another GSK3 inhibitor, inhibitor VIII (16 µM), also substantially protected against NIFAR, although slightly less effectively ( Table 1) . Inhibition of cyclin dependent kinase 5 (cdk5) has been reported to mediate some of the effects of lithium [18] . However, the cdk inhibitor roscovitine (10 µM; 1 h to 7 days) did not protect against NIFAR (Table 1) .
We next asked whether phosphoinositide-3-kinase (PI3 kinase), which acts through Akt kinases as an upstream activator of GSK3 [11, 15] , was involved in NIFAR. A 30-min preincubation with the specific PI3 kinase inhibitor LY 294002 prevented NIFAR (Fig. 2b) . In addition to its inhibition of GSK3, lithium is known to inhibit myoinositol monophosphatase, which can lead to myoinositol depletion [10, 11] . However, addition of myoinositol (5 mM, 7 days) to the incubation medium, together with LiCl, did not reverse the protective effect of lithium (Table 1) .
Fluoxetine and imipramine reduce NIFAR
We asked whether, in addition to lithium, other mood stabilizers or antidepressants would have a similar protective effect against NIFAR or whether this was a specific characteristic of lithium. The anticonvulsants valproate and carbamazepine are used to treat bipolar disorder [11] . In our model, neither valproate (1 mM; 1 h to 7 days) nor carbamazepine (100 µM; 1 h to 7 days) protected against NIFAR (Table 1) . However, two classes of antidepressants showed partial protection against NIFAR. The selective serotonin reuptake inhibitor fluoxetine (10 µM; 0.5-4 h) partially prevented NIFAR (Fig. 3a) . The tricyclic antidepressant imipramine (20 µM) strongly attenuated NIFAR; however, it was only effective with 0.5 and 1 h preincubations, and a 4 h preincubation was ineffective (Fig. 3b) . 
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Discussion
Numerous studies have demonstrated a neuroprotective and antiapoptotic role of lithium in neuronal cell cultures. However, the precise mechanisms by which this protection occurs remain to be elucidated [9] [10] [11] [12] [13] 15] . Although chronic lithium administration was shown to block excitotoxic cell death induced by glutamate agonists [19] , our study is the first to characterize the effect of lithium on early acute changes in the actin cytoskeleton induced by increased levels of glutamate agonists. Such excess glutamate represents a cellular stress condition that potentially underlies circuit disruption in disorders ranging from neurodegeneration, stroke, and epilepsy, to mood disorders and schizophrenia [20, 21] .
Here we describe NIFAR as a rapid and extensive reorganization of the dendritic actin cytoskeleton in response to hyperactivation of NMDA receptors. NIFAR represents an early stage in the neuronal cellular stress response. It is thus a quantifiable read-out of glutamateinduced injury to dendrites and spines. The mechanisms underlying NIFAR are currently under investigation; however, they may involve oxidative changes, as described in other forms of cellular stress [22] .
NIFAR includes rapid disassembly of F-actin within dendritic spines, and simultaneous accumulation of F-actin in the dendritic shaft [7] . A similar phenomenon was described for NMDA-induced relocalization of the actin binding proteins IP 3 kinase [8] and drebrin [23] . Neurons that undergo NIFAR also exhibit dendritic spine shrinkage and loss [7] , a potential mediator of neural circuit disruption in mood disorders. Importantly, NIFAR occurs not only in dissociated cultured neurons, but also in vivo in a rodent model of traumatic brain injury (Calabrese, Krajewski and Halpain, unpublished), a clinical condition associated with prolonged elevations of extracellular glutamate and excess NMDA receptor activation [24] . Further studies are needed to examine whether an NIFAR-like phenomenon is associated with more subtle levels of cellular stress and impaired plasticity that may occur in mood disorders.
Lithium is known to affect a multitude of biochemical and cell signaling pathways, and it is likely that its therapeutic efficacy may involve a spectrum of its many targets, including those that engage the cytoskeleton and those involved in neuroprotection [25] . Our results indicate that lithium may protect neurons against NIFAR through inhibition of GSK3 activity, although additional studies are needed to confirm this hypothesis. Here, we show that GSK3 inhibitors mimic the protective effect of lithium in preventing NIFAR. GSK3 is a ubiquitous Ser/Thr protein kinase with proapoptotic properties that phosphorylates a variety of substrates, including cytoskeletal substrates such as the Alzheimer's disease-related microtubuleassociated protein tau [26] and specific actin regulatory molecules [27] .
Lithium is also known to regulate specific neuromodulators, including serotonin, [25] and it is therefore possible that the protective effects of lithium against NIFAR Hippocampal neurons grown for 3 weeks in culture were treated with a variety of drugs before NMDA treatment, were fixed, and were stained for F-actin. Neurons with NIFAR were scored as described in the Methods section.
Values indicate average percent reduction over multiple replicants. are mediated through one or more of these systems. Indeed, the protective effect of fluoxetine and imipramine that we observed is consistent with a role for the serotonergic system in NIFAR. Lithium reportedly inhibits the presynaptic 5-HT 1B autoreceptor, resulting in increased serotonin release into the synaptic cleft [28] . Direct inhibition of 5-HT reuptake by either fluoxetine or imipramine would have a similar effect on synaptic 5-HT levels. Moreover, Jope and colleagues have shown that fluoxetine and imipramine inhibit GSK3 activity [29] , suggesting that GSK3 inhibition may represent a common pathway for many of the effects of lithium. Therefore, it will be of interest to further explore a potential connection between NIFAR and serotonin.
Remarkably, several compounds used in this study were rapidly effective in preventing NIFAR. The GSK3 inhibitor SB216763, the PI3 kinase inhibitor LY 294002, and the antidepressant drugs fluoxetine and imipramine all effectively prevented NIFAR with 0.5-1 h preincubation, in contrast to the several days of preincubation that were required for LiCl.
This difference in time course might indicate that the protective action of lithium involves additional changes in gene expression or other factors that accumulate over time. For example, lithium is reported to elevate the expression of the neurotrophic factor Brain-derived neurotrophic factor (BDNF), which has been implicated in lithium-mediated neuroprotection [9] [10] [11] [12] [13] [14] . Other studies similarly reported that multiple days of lithium exposure are needed to reveal its full neuroprotective efficacy in vitro [11] , and therapeutic doses of lithium in bipolar patients typically require multiple days of treatment before behavioral benefits become stabilized [11, 12] .
Our data appear to exclude a role of either cdk5 or myoinositol pathways in mediating the protective effect of LiCl against NIFAR. The clinically effective mood stabilizers carbamazepine and valproate have distinct molecular targets from those of LiCl [11] , and in our studies, these drugs appear not to mediate protection against NIFAR at the times and dosage tested.
Conclusion
We observed that lithium, fluoxetine, and imipramine protected cultured neurons from rapid NMDA-induced aberrant changes in the dendritic actin cytoskeleton, including actin loss from dendritic spines. These findings suggest that certain mood stabilizers may exert their therapeutic potential, in part, through actin-based mechanisms that regulate postsynaptic structural stability and/or neural plasticity. GSK3 inhibitors mimicked the protective effect of lithium. Further studies will be needed to establish whether lithium and other mood stabilizers act through this pathway to stabilize the neuronal structure as a part of their therapeutic actions.
